The objective of this study was to analyze the safety of long-term infl iximab treatment, with / without concomitant immunomodulators, across Crohn ' s disease (CD) and ulcerative colitis (UC) clinical trials.
INTRODUCTION
Infl ammatory bowel disease (IBD) is a chronic, infl ammatory disorder of the gastrointestinal tract. As such, standard therapies for IBD have focused on nonspecifi c inhibition of infl ammation with sulfasalazine, mesalazine, steroids, the thiopurines azathioprine (AZA) and 6-mercaptopurine (6-MP), and methotrexate (MTX) ( 1 ) . While these agents can be moderately eff ective in maintaining corticosteroid-induced remission, relapse can be common ( 2, 3 ) . In addition, thiopurine therapy of IBD carries an increased risk of lymphoproliferative disorders ( 4 ) .
On the basis of the unmet need for patients intolerant of or unresponsive to standard therapy, several antagonists of the proinfl ammatory cytokine tumor necrosis factor (TNF) have been developed, including adalimumab, etanercept, infl iximab, and certolizumab pegol. Although TNF antagonist therapy is generally well tolerated by patients with IBD, a unique spectrum of safety issues related to blocking TNF, including life-threatening and opportunistic infection, malignancy, and mortality, must be considered. While researchers have attempted to obtain consensus on the relationship between TNF antagonist therapy and A Pooled Analysis of Infections, Malignancy, and Mortality in Infl iximab-and Immunomodulator-Treated Adult Patients With Infl ammatory Bowel Disease these relatively rare events, analyses have generally been limited by comparatively small study populations and short periods of patient follow-up.
Th e TNF antagonist infl iximab has been used to treat patients with moderately-to-severely active IBD for more than a decade. As infl iximab was approved for the treatment of moderate-tosevere Crohn ' s disease (CD), the sponsor has conducted several large, randomized, controlled phase 3 clinical trials of infl iximab maintenance therapy in IBD (hereaft er referred to as " pivotal phase 3 trials " ), including the ACCENT I ( 5,6 ), ACCENT II ( 7 ), and SONIC ( 8 ) trials in CD and the ACT 1 and ACT 2 trials ( 9 ) that formed the basis for approval of infl iximab in ulcerative colitis (UC).
Although safety fi ndings related to each of these studies have been reported in separate publications, a pooled analysis of key safety outcomes has been recently conducted for all sponsor-initiated infl iximab trials in IBD, with emphasis on the fi ve pivotal phase 3 trials that contribute nearly 90 % of the data for patients in the pooled IBD safety analyses. Given the continued need for safety data related to TNF antagonism, fi ndings of these analyses are detailed herein.
METHODS
Th e 10 (7 CD, 3 UC) clinical trials included in these pooled analyses represent the totality of the sponsor ' s clinical safety database for infl iximab in the treatment of adult patients with IBD. Th e pooled studies comprise fi ve smaller trials (4 CD, 1 UC) evaluating a total of 244 patients ( 10 -15 ), 22 of whom contributed data to more than one treatment group per study, and fi ve pivotal phase 3 trials evaluating infl iximab maintenance therapy in 1,644 patients with CD ( 5 -8 ) and 741 patients with UC ( 9 ) , 184 of whom contributed data to more than one treatment group per study ( Tables 1 -5 ) .
Th e fi ve pivotal phase 3 trials, i.e., ACCENT I, ACCENT II, SONIC, ACT 1, and ACT 2, contributed approximately 89 % (2,119 / 2,385) of all patients with data in the overall pooled analyses and were generally consistent in terms of study designs, in that they were all randomized, multicenter, double-blind trials that included a control group ( Table 1 ). Note that for four of the fi ve pivotal phase 3 trials (ACCENT I, ACCENT II, ACT 1, and ACT 2), treatment with the immunomodulators AZA, 6-MP, and MTX or with corticosteroids was allowed during study participation, but such use was not a randomized study treatment. Each of these study protocols stipulated that patients would continue a stable regimen of baseline immunomodulator therapy throughout study participation. Conversely, the SONIC trial enrolled exclusively immunomodulator-na ï ve patients, and these patients were randomized to receive AZA, 5 mg / kg of infl iximab, or AZA plus 5 mg / kg of infl iximab ( 8 ) .
All study protocols were approved by the institutional review board at each participating site, and all patients provided written informed consent before beginning study participation. Janssen Biotech, Inc. (Horsham, PA) provided infl iximab, active comparator (AZA in the SONIC trial), and placebo (as appropriate) for intravenous infusion.
To evaluate the occurrence of uncommon events, safety data from the seven studies in CD (with the majority of the data coming from the pivotal ACCENT I, ACCENT II, and SONIC studies) were pooled and are reported as ' CD studies ' . When pooled with data from the three ' UC studies ' (with the majority of the data deriving from the pivotal ACT 1 and ACT 2 studies), they are reported as ' IBD studies ' . Safety data from the pivotal phase 3 trials in IBD, i.e., ACCENT I, ACCENT II, SONIC, ACT 1, and ACT 2, were also separately pooled across the three CD, two UC, and all fi ve pivotal phase 3 IBD studies. Summaries of key design features of these studies are provided in Table 1 .
Th e incidences of adverse events per 100 patient-years (pt-yrs) of follow-up were calculated for infections, malignancies (including both solid tumors and hematological malignancies and excluding nonmelanoma skin cancers) and deaths by treatment group (infl iximab vs. placebo) and also by immunomodulator use (treatment vs. no treatment) for infections and malignancies as the quotient of the total number of events and pt-yrs of follow-up multiplied by 100; exact 95 % confi dence intervals (CIs) were also calculated.
For malignancies (excluding nonmelanoma skin cancer), standardized incidence ratios (SIRs) were also calculated as the quotient of the observed and expected numbers of patients with malignancy; 95 % CIs were determined using exact methodology. Th e expected numbers of malignancy were derived using data adjusted for age, sex, and race from the general US population in the Surveillance, Epidemiology, and End Results (SEER) database ( 16 ).
Fisher ' s exact test was used to compare the proportions of patients who experienced an adverse event of interest (e.g., infection, malignancy, or death) between treatment groups. Because a large number of safety parameters were evaluated, the Fisher ' s exact test is employed not for hypothesis testing but rather as an aid in signal detection to highlight diff erences requiring closer examination.
All patients in ACCENT I and ACCENT II received infl iximab 5 mg / kg at week 0 and were therefore counted in the infl iximab column in the calculation of pt-yrs of follow-up. Pt-yrs of follow-up for placebo were determined for the 161 placebo plus AZA-treated CD patients in the SONIC study plus additional placebo-treated patients from other CD studies (T08, T11, T16, and T20; see Table 1 ) as applicable to the subpopulation being assessed. Note that infl iximab use, both in combination with immunomodulators and alone, and immunomodulator use, both in combination with infl iximab and alone, are pooled in these analyses such that infl iximab use refers to any use of infl iximab and immunomodulator use refers to any use of immunomodulators. Also note that the placebo group includes only patients who never received infl iximab.
As noted above, infl iximab treatment was generally randomized and blinded, while immunomodulator treatment, with the exception of the SONIC trial, refl ects immunomodulator use at baseline, i.e., immunomodulator use was not randomized or blinded and assumes that such use continued during the study. Protocols for these four of fi ve pivotal phase 3 trials mandated that patients receiving a stable immunomodulator regimen at baseline would continue such use throughout study participation. 
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RESULTS
Analysis groups and extent of exposure
Across the 10 sponsor-initiated infl iximab trials in IBD (fi ve smaller studies and fi ve pivotal phase 3 studies conducted following infl iximab ' s initial approval), safety data for 2,385 patients were available for pooled safety analyses (see Tables 3 -5 ). Note that some patients presented in Tables 1 and 2 contributed data to more than one treatment group in the analyses presented in Tables 3 -5 , e.g., 22 of the 244 patients in the fi ve smaller studies and 33 of the 2,086 patients in the fi ve pivotal trials. Data from the fi ve pivotal trials were pooled for additional analyses, both across all fi ve studies ( n = 2,119) and across the three CD studies ( n = 1,389) or 2 UC ( n = 730) studies due to similarities in study design and homogeneity of the patient populations. In the 5 pivotal IBD trials, 406 and 1,713 patients were treated with placebo and infl iximab, respectively ( ( Tables 3 and 5 ) . Th e extent of exposure to individual study agents for each of the pivotal phase 3 trials is summarized in Table 2 , which includes infl iximab infusions received during the main studies, as well as the blinded study extensions of SONIC and ACT 2. Excluding patients who initially received infl iximab but who were later randomized to placebo maintenance treatment, CD patients received an average of 6.1 -7.5 infl iximab infusions and UC patients received an average of 6.3 -6.5 infl iximab infusions. Note that study agent administration in the SONIC and ACT 2 main studies ended with the week-22 infusion and that safety data from week 30 through week 54 were collected as part of a blinded study extension, during which patients continued to receive blinded study agent. 
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Pooled Safety Analyses of Infliximab in IBD system disorders (0.94 and 0.97 / 100 pt-yrs). Within these three system -organ classes, the most common serious infections were abscess (1.57 and 1.89 / 100 pt-yrs in placebo-and infl iximab-treated IBD patients, respectively), gastro enteritis (0.63 and 0.26 / 100 pt-yrs), and pneumonia (0.31 and 0.66 / 100 pt-yrs) ( Table 3 ) .
Malignancy
Across the 10 IBD trials and excluding nonmelanoma skin cancers, 13 patients (two placebo-treated, 11 infl iximab-treated) had a malignancy during study participation. Of the malignancies, 11 were non-lymphoma, while two patients had lymphoma. Both patients with lymphoma were infl iximab-treated CD patients. One patient who received infl iximab 5 mg / kg at week 0 followed by placebo maintenance and AZA had natural killer cell lymphoma diagnosed aft er study participation ended. A second patient with a history of AZA use received a single infusion of infl iximab 10 mg / kg and was diagnosed with intravascular B-cell lymphoma 9.5 months aft er the single infl iximab infusion. Th e non-lymphoma malignancies included breast ( n = 2), colon ( n = 2), prostate ( n = 2), bladder ( n = 1), lung ( n = 1), renal ( n = 1), skin ( n = 1), and rectal ( n = 1) cancers (9 infl iximab-treated, 2 placebo). When expressed on the basis of incidence (95 % CI) per 100 pt-yrs of follow-up, overlapping 95 % CIs indicated that the incidences of malignancies were similar in the placebo-and infl iximab-treated patients with CD (1.61 (0.19, 5.82) vs. 0.49 (0.18, 1.06), respectively) and with UC (0.00 (0.00, 1.43) vs. 0.60 (0.20, 1.40), respectively). Findings observed within the lymphoma and non-lymphoma malignancy subcategories were similar ( Table 4 ) .
Th e incidences of malignancies during only the controlled portions of the 10 IBD trials were also determined. Four patients, two placebo-treated and two infl iximab-treated, had a malignancy during the controlled study phases. No cases of lymphoma were documented during the controlled portions of the 10 IBD studies.
Infections
Th e incidences of infections and serious infections were determined across the fi ve pivotal phase 3 IBD trials. A larger proportion of infl iximab-than placebo-treated UC patients (50.1 % vs. 36.3 % ; P < 0.001) had at least one infection. Among CD patients, however, the proportions of patients who experienced at least one infection were similar between the infl iximab-and placebotreated patients (49.1 % vs. 45.3 % ; P = 0.402). Th e proportions of patients who experienced at least one serious infection were also similar between placebo-and infl iximab-treated patients ( ( Table 3 ) .
When assessed by the patient ' s baseline immunomodulator treatment (yes / no), the 95 % CIs surrounding the incidences of infections and serious infections overlapped between patients treated with immunomodulators and those not treated with immunomodulators in all patient populations (CD, UC, all IBD), with one exception. In patients with UC, but not CD, immunomodulator treatment (vs. no treatment) yielded a higher incidence (95 % CI) of infections (120.07 (110.66, 130.08) / 100 pt-yrs vs. 92.47 (84.54, 100.94) / 100 pt-yrs) ( Table 3 ) .
A summary of the incidences of serious infections (per 100 pt-yrs of follow-up) by system -organ class and preferred term is also provided in Table 3 . Th e most common serious infections were those considered resistance mechanism disorders (3.15 and 3.32 / 100 ptyrs in placebo-and infl iximab-treated IBD patients, respectively), gastrointestinal disorders (0.63 and 1.07 / 100 pt-yrs), and respiratory In ACCENT II, placebo patients received 5 mg / kg infl iximab at weeks 0, 2, and 6 before randomization at week 14, and some of them also crossed over to receive infusions of infl iximab 5 mg / kg. c Including infl iximab infusions received during the main study and the blinded study extension.
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Further, in all three of the patient populations (CD, UC, and all IBD), the 95 % CIs surrounding the incidences of malignancy overlapped when compared between patients who were treated vs. those who were not treated with immunomodulators, with one exception. Among placebo-treated patients with CD, but not UC, those with immunomodulator use demonstrated a higher incidence (95 % CI) of malignancy vs. no immunomodulator treatment (1.84 (0.22, 6.66) / 100 pt-yrs vs. 0.00 (0.00, 0.00) / 100 pt-yrs).
In a separate analysis comparing the observed incidences of malignancy with rates expected in the general US population based on the SEER database, all 95 % CIs surrounding the malignancy SIRs contained 1 in all analysis groups (i.e., placebo and infl iximab, with and without baseline immunomodulator use). Th is indicates that the incidences of malignancy observed in the controlled portions of the pivotal phase 3 trials are not signifi cantly diff erent from the expected rates in the general US population. Similar fi ndings were observed within the lymphoma and non-lymphoma malignancy subcategories ( Table 4 ) .
When comparing the proportions of patients who had malignancy diagnosed during the studies (both overall and during the controlled portions), results of Fisher ' s exact testing indicated no significant diff erence between infl iximab-and placebo-treated patients ( Table 4 ) .
Further, when expressed as incidence (95 % CI) per 100 pt-yrs of follow-up, the incidences of malignancy appeared similar in placebo-vs. infl iximab-treated patients with CD (1.65 (0.20, 5.97) vs. 0.00 (0.00, 1.00), respectively) and UC (0.00 (0.00, 2.18) vs. 0.60 (0.07, 2.17), respectively). Consistent fi ndings were observed within the lymphoma and non-lymphoma malignancy subcategories ( Table 4 ) .
Th e incidence of malignancy was also assessed by immunomodulator use in the controlled portions of the fi ve pivotal phase 3 IBD trials. When comparing the proportions of patients who had malignancy diagnosed during the studies (both overall and during the controlled portions), results of Fisher ' s exact testing indicated no signifi cant diff erence between infl iximab-and placebo-treated patients or between patients with and without immunomodulator use ( Table 4 ) . AZA, azathioprine; CI, confi dence interval; IBD, infl ammatory bowel disease; 6-MP, 6-mercaptopurine; MTX, methotrexate; pts., patients; pt-yrs, patient-years; SEER, Surveillance, Epidemiology, and End Results; SIR, standardized incidence ratio. a Includes 7 Crohn's disease and 3 ulcerative colitis, and thus a total of 10, IBD studies.
b Includes 3 Crohn's disease and 2 ulcerative colitis, and thus a total of 5 pivotal phase 3 IBD studies. c With or without concomitant conventional therapy. P -values comparing treatment or immunomodulator use subgroups were calculated with the use of Fisher's exact test. Note that P -values cannot be computed when a group has no patients or when neither group has such an event. e 95 % CIs based on an exact method. In addition to the malignancies discussed above, among the 2,385 patients with IBD included in these analyses (465 placebo, 1,920 infl iximab), fi ve patients (3 infl iximab-treated, 2 placebo-treated) had basal cell carcinoma and two patients (both infl iximab-treated) had malignant skin neoplasm.
Mortality
Five patients died during the 10 IBD trials. Th e deaths included a patient (63-year-old female with baseline immunomodulator use) with CD in SONIC who received AZA monotherapy and died of sepsis following a colectomy; three infl iximabtreated patients with CD in ACCENT I who died of septic shock (35-year-old female with no baseline immunomodulator use), sepsis (57-year-old female with no baseline immunomodulator use), and myocardial infarction (37-year-old male with baseline immunomodulator use); and one infl iximab-treated patient with UC in ACT 2 (56-year-old male with baseline immunomodulator use) who died following diagnosis of pulmonary histoplasmosis during the open-label, long-term, follow-up period.
Given the longer follow-up periods for infl iximab-treated patients, when summarized as incidence (95 % CI) per 100 pt-yrs of follow-up, overlapping CIs indicated no increase in mortality with infl iximab vs. placebo treatment among patients with CD (0. 24 
Infection-related deaths
No. ( % ) of pts. 
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Pooled Safety Analyses of Infliximab in IBD to the relatively low incidence of serious infections, regardless of immunomodulator use, as such an eff ect could off set any small increase in serious infections that might be associated with the immunosuppressive nature of these drugs. Th ese fi ndings are also consistent with additional data from the TREAT Registry that indicated that the risk for serious infection in infl iximabtreated CD patients is similar to that for patients receiving conventional immunomodulators ( 21 ) . Despite our observation of no increase in serious infections, all patients should be screened for pre-existing infections before the start of any immunosuppressive therapy.
Overall, 13 patients (2 placebo-treated, 11 infl iximab-treated) had a malignancy (excluding nonmelanoma skin cancer) during the 10 IBD trials, equating to incidences of 0.60 and 0.53 / 100 ptyrs, among placebo-and infl iximab-treated IBD patients, respectively. Two of the malignancies in infl iximab-treated CD patients were lymphomas; the 11 other malignancies across both cohorts were non-lymphoma.
During the controlled portions of the 10 IBD trials, four patients (2 placebo, 2 infl iximab) had a malignancy, all non-lymphoma, equating to incidences of 0.77 and 0.32 / 100 pt-yrs, respectively, of placebo-and infl iximab-treated IBD patients. Th e incidence of malignancy was not higher with infl iximab treatment, nor was it signifi cantly impacted by immunomodulator use. In a separate analysis comparing the observed incidences of malignancy with rates expected in the general US population based on the SEER database, the incidence of malignancy was not signifi cantly diff erent.
A higher incidence of malignancy was observed in placebotreated patients receiving vs. those not receiving immunomodulators. Th ese fi ndings may support others suggesting that the thiopurines AZA and 6-MP are associated with a moderately increased risk of malignancy, particularly lymphoproliferative disease. Specifi cally, in a French cohort of nearly 20,000 patients with IBD (60 % with CD, 40 % with UC or unclassifi ed IBD) followed for an average of 35 months, the risk of lymphoproliferative disorder was 5 times higher in patients exposed to thiopurines than in those never exposed to these drugs. Older age, male sex, and longer duration of IBD were also associated with increased risk of lymphoproliferative disorder in the French cohort ( 22 ) . Also, as noted above, results of a retrospective safety analysis of 799 German IBD patients treated with thiopurines and / or TNF antagonists between 2002 and 2010 indicated an elevated risk of malignancy (4.2 % vs. 1.5 % , P = 0.024, odds ratio = 2.86) in patients treated with only thiopurines relative to patients treated with TNF antagonists with or without thiopurines ( 20 ) .
We also determined malignancy SIRs within the groups of patients with and without baseline immunomodulator use. Results of these pooled analyses indicated no signifi cant diff erence from the expected rates in the general US population. Conversely, recently reported results of a meta-analysis of 26 studies of infl iximab, adalimumab, and certolizumab, including almost 9,000 CD patients, indicated that use of anti-TNF agents with immunomodulators is associated with an increased, albeit small (6.1 / 10,000 pt-yrs), risk of non-Hodgkin ' s lymphoma relative to accounted for four of the fi ve deaths. Overlapping 95 % CIs were also observed in a separate analysis of mortality by immunomodulator use in the fi ve pivotal phase 3 IBD trials ( Table 5 ).
DISCUSSION
Since receiving marketing authorization for the treatment of CD more than a decade ago, infl iximab has gained wide acceptance as a highly eff ective treatment option for IBD. As a result, longer-term safety data are becoming available. No diff erence in the incidence of neoplasia between adult patients with CD who were ( n = 404) and were not ( n = 404) treated with infl iximab was reported by Biancone et al ( 17 ) . An additional 4 years of follow-up of 591 of the patients in this matched-pair study yielded consistent fi ndings, with 3.9 % (12 / 304) of infl iximabtreated patients and 4.2 % (12 / 287) of patients not treated with infl iximab diagnosed with neoplasia ( P = 0.95) ( 18 ) . Fidder et al. ( 19 ) , who retrospectively examined medical records of 734 infl iximab-treated IBD patients and 666 controls, also observed no diff erence between the two groups in mortality, malignancy including lymphoma, or infection rate. In a retrospective safety analysis of 799 German IBD patients treated with thiopurines and / or TNF antagonists between 2002 and 2010, an elevated risk of malignancy (4.2 % vs. 1.5 % , P = 0.024, odds ratio = 2.86), but not infection (14.4 % vs. 15.5 % , P = 0.69), was observed in patients treated with only thiopurines relative to patients treated with TNF antagonists with or without thiopurines ( 20 ) . Results of several large randomized phase 3 clinical trials of infl iximab maintenance therapy in IBD, including the ACCENT I ( 5,6 ), ACCENT II (7), and SONIC ( 8 ) trials in CD and the ACT 1 and ACT 2 trials ( 9 ) in UC also contribute to the growing body of infl iximab safety data.
Findings presented herein from a pooled analysis of key safety outcomes, derived from 10 sponsor-conducted IBD studies with large cohorts of IBD patients treated by referral centers in daily practice, are generally consistent with conclusions drawn by Biancone et al. ( 17, 18 ) and Fidder et al. ( 19 ) . Specifi cally, results of our pooled analyses of infl iximab safety data in the treatment of IBD indicate no increase in infections or serious infections with infl iximab vs. placebo treatment in patients with CD or UC. Independent of infl iximab use, immunomodulator treatment did not appear to increase the incidence of infections or serious infections in patients with CD but did yield a higher incidence of infection vs. no immunomodulator treatment in patients with UC. One explanation for the lack of an increase in the incidence of serious infections with either infl iximab or immunomodulators in CD is that many of the complications of CD are inherently infectious in nature and may be decreased by eff ective CD therapy. Results derived from the TREAT Registry of CD patients, which included assessment of the role of corticosteroids in infectious complications, have shown that infl iximab allows for steroid tapering and discontinuation in CD ( 21 ) . Several of the protocols for the pivotal phase 3 trials included in this report mandated steroid tapering during the early phase of the trial. Th e lower steroid consumption in the reported CD trials may also contribute
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the expected rate of non-Hodgkin ' s lymphoma derived from the SEER database, i.e., 1.9 / 10,000 pt-yrs (SIR (95 % CI) = 3.23 (1.5, 6.9)), and also relative to the expected rate for CD patients treated with only immunomodulators, i.e., 4.0 / 10,000 pt-yrs (SIR (95 % CI) = 1.70 (0.5, 7.1)) ( 23 ). As noted above, no cases of lymphoma were reported during the controlled portions of the trials comprising our pooled analyses. In addition to the malignancies discussed above, among the 2,385 patients with IBD included in these analyses (465 placebo, 1,920 infl iximab), fi ve patients (3 infl iximab-treated, 2 placebo-treated) had basal cell carcinoma and two patients (both infl iximab-treated) had nonmelanoma malignant skin neoplasm. It is still not certain whether or not infliximab use increases the risk of malignancy, but it is possible that the impact of infl iximab is no worse than that of conventional immunomodulators and that, by eff ectively controlling infl ammation, infl iximab may contribute to a lower malignancy risk in IBD. Th e latter possibility requires further confi rmation with longer-term data.
Consistent with published reports citing no evidence of increased mortality in CD patients treated with anti-TNF agents ( 19, 20, 24 ) , we observed no diff erence in mortality between placebo-and infl iximab-treated patients with either CD or UC. Th e same was true for infection-related deaths, which accounted for four of the fi ve deaths. Immunomodulator treatment was also unassociated with increases in mortality in these IBD patients.
One point to note in the interpretation of these data is that, with the exception of the SONIC trial ( 8 ), immunomodulator treatment was not randomized, blinded, or controlled and refl ects patient treatment at the time of study entry (as study protocols stipulated that any baseline immunomodulator treatment regimen would remain stable throughout study participation). It therefore remains possible that any higher event incidence in the immunomodulator-treated patients refl ects their having more severe IBD rather than immunomodulator use itself. For this reason, any comparison between event rates between infliximab vs. immunomodulators must be made with caution. Still, the data of Fidder et al. ( 19 ) showed no diff erence in the rates of infection, malignancy including lymphoma, and mortality between IBD patients treated with infl iximab and IBD patients treated with conventional therapies. It should also be noted, however, that the overall pooled results do not diff er from those of the SONIC trial, in which both treatment with infl iximab and treatment with immunomodulators were randomized in a controlled trial. It is also important to note that the relatively short period of follow-up, along with the relative lack of power inherent in these clinical trial data for determining treatment group diff erences in rare safety events, limit our ability to draw defi nitive conclusions from these analyses. Th e powering, however, is fairly good for detecting a doubling or tripling of the malignancy rate, both of which are clinically important to exclude. Th e 2,061 pt-yrs of follow-up from the infl iximab-treated IBD cohort in this paper would yield 71 % or 99 % power to detect a doubling or tripling in malignancy incidence, respectively. Representing data derived from rigorous clinical trials, therefore, the current data are somewhat reassuring and have merit when assessing the overall safety of anti-TNF agents.
When taken together, results of these pooled analyses indicate no increase in serious infection, mortality, or malignancy, including lymphoma in association with infl iximab treatment of IBD. In addition, the safety of infl iximab in these analyses appears comparable to that of conventional immunomodulators.
